The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

After several reports of increased blood pressure, heart rate and sudden death in attention deficit-hyperactivity disorder or ADHD patients, the FDA advised drug makers to amend the labels of the drugs like Ritalin to reflect concerns about cardiovascular and psychiatric problems.

“In our ongoing commitment to strengthen drug safety, FDA is working closely with manufacturers of all ADHD medicines to include important information in the product labeling and in developing new Patient Medication Guides to better inform doctors and patients about these concerns.”

ADHD, which is characterized by three major symptoms, inattention, hyperactivity and impulsivity, affects 3 to 7 per cent of schoolchildren and 4 percent of adults. An estimated 2 million people in the U.S. suffer from this condition.

Comments are closed.

Of Interest